Document and Entity Information
Document and Entity Information - USD ($) | 12 Months Ended | ||
Dec. 31, 2015 | Apr. 13, 2016 | Jun. 30, 2015 | |
Document and Entity Information: | |||
Entity Registrant Name | AXIM BIOTECHNOLOGIES, INC. | ||
Entity Trading Symbol | axim | ||
Document Type | 10-K | ||
Document Period End Date | Dec. 31, 2015 | ||
Amendment Flag | false | ||
Entity Central Index Key | 1,514,946 | ||
Current Fiscal Year End Date | --12-31 | ||
Entity Common Stock, Shares Outstanding | 39,762,659 | ||
Entity Filer Category | Smaller Reporting Company | ||
Entity Current Reporting Status | Yes | ||
Entity Voluntary Filers | No | ||
Entity Well-known Seasoned Issuer | No | ||
Document Fiscal Year Focus | 2,015 | ||
Document Fiscal Period Focus | FY | ||
Entity Public Float | $ 37,000,000 |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) | Dec. 31, 2015 | Dec. 31, 2014 |
Current assets: | ||
Cash | $ 134,170 | $ 661,128 |
Inventory | 200,784 | 0 |
Reservation fee deposit | 65,170 | 0 |
Prepaid expenses | 777,657 | 72,329 |
Loan receivable | 5,000 | 5,000 |
Total current assets | 1,182,781 | 738,457 |
Property & Equipment, net of accumulated depreciation of $1,119 | 15,661 | 0 |
Other Assets: | ||
Acquired intangible asset - intellectual property licensing agreement | 63,167 | 0 |
Total other assets | 63,167 | 0 |
TOTAL ASSETS | 1,261,609 | 738,457 |
Current liabilities: | ||
Accounts payable and accrued liabilities | 392,937 | 144,385 |
Due to shareholder | 5,000 | 5,000 |
Convertible loan | 50,000 | 50,000 |
Due to first insurance funding | 22,964 | 54,020 |
Due to related party | 1,085,910 | 65,775 |
Promissory note - related party | 1,000,000 | 1,000,000 |
Total current liabilities | 2,556,811 | 1,319,180 |
Long-term liabilities: | ||
Convertible note payable | 400,000 | 0 |
Total long-term liabilities | 400,000 | 0 |
TOTAL LIABILITIES | 2,956,811 | 1,319,180 |
STOCKHOLDERS' DEFICIT | ||
Preferred stock, $0.0001 par value, 5,000,000 shares authorized;Series A Convertible Preferred stock, $0.0001 par value, 1,000,000 shares designated, 1,000,000 and 0 shares issued and outstanding; respectively. | 100 | 0 |
Undesignated Preferred stock, $0.0001 par value, 4,000,000 shares authorized,1,000,000 shares issued and outstanding | 100 | 100 |
Common stock, $0.0001 par value, 300,000,000 shares authorized 39,633,706 and 33,000,000 shares issued and outstanding, respectively; | 3,963 | 3,300 |
Additional paid in capital | 9,032,865 | 107,841 |
Common stock to be issued | 52,500 | 0 |
Accumulated deficit | (10,784,730) | (691,964) |
TOTAL STOCKHOLDERS' DEFICIT | (1,695,202) | (580,723) |
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT | $ 1,261,609 | $ 738,457 |
Consolidated Balance Sheets Par
Consolidated Balance Sheets Parentheticals - USD ($) | Dec. 31, 2015 | Dec. 31, 2014 |
Parentheticals | ||
Property & Equipment, accumulated depreciation | $ 1,119 | $ 1,119 |
Preferred Stock, Par or Stated Value | $ 0.0001 | $ 0.0001 |
Preferred Stock, Shares Authorized | 5,000,000 | 5,000,000 |
Series A Convertible Preferred stock,Par or Stated Value | $ 0.0001 | $ 0.0001 |
Series A Convertible Preferred stocK,shares Authorized | 1,000,000 | 1,000,000 |
Designated Preferred Stock Shares Authorized | 1,000,000 | 1,000,000 |
Designated Preferred Stock Shares Issued | 0 | 0 |
Designated Preferred Stock Shares Outstanding | 0 | 0 |
Undesignated Preferred stock, Par or Stated Value | $ 0.0001 | $ 0.0001 |
Undesignated Preferred stock Shares Authorized | 4,000,000 | 4,000,000 |
Undesignated Preferred stock,Shares Issued | 1,000,000 | 1,000,000 |
Undesignated Preferred stock,Shares Outstanding | 1,000,000 | 1,000,000 |
Common Stock, Par or Stated Value | $ 0.0001 | $ 0.0001 |
Common Stock, Shares Authorized | 300,000,000 | 300,000,000 |
Common Stock, Shares Issued | 39,633,706 | 33,000,000 |
Common Stock, Shares Outstanding | 39,633,706 | 33,000,000 |
Consolidated Statement of Opera
Consolidated Statement of Operations - USD ($) | 12 Months Ended | |
Dec. 31, 2015 | Dec. 31, 2014 | |
Revenues {1} | ||
Revenues | $ 49,139 | $ 0 |
Cost of goods sold | 50,387 | 0 |
Gross loss | (1,248) | 0 |
Expenses: | ||
Research and development expenses | 571,455 | 0 |
Selling, General and administrative | 9,475,723 | 505,729 |
Depreciation | 1,119 | 0 |
Total operating expenses | 10,048,297 | 505,729 |
Loss from operations | (10,049,545) | (505,729) |
Other (Income) expenses: | ||
Interest expense | 43,221 | 32,522 |
Total other income and Expense | 43,221 | 32,522 |
Loss from Continuing operation before provision of income tax | (10,092,766) | (538,251) |
Provision for income tax | 0 | 0 |
LOSS FROM CONTINUING OPERATION | (10,092,766) | (538,251) |
LOSS FROM DISCONTINUED OPERATION | 0 | (44,696) |
NET LOSS | $ (10,092,766) | $ (582,947) |
Loss per common share from continuing operation- basic and diluted | $ (0.27) | $ (0.02) |
Loss per common share from discontinued operation- basic and diluted | 0 | 0 |
Loss per common share - basic and diluted | $ (0.27) | $ (0.02) |
Weighted average common shares outstanding - basic and diluted | 37,054,770 | 33,000,000 |
Consolidated Statement of Stock
Consolidated Statement of Stockholders' Deficit - USD ($) | Common Stock Shares | Common Stock Amount | Preferred Stock Shares | Preferred Stock Amount | Series A Convertible Shares | Series A ConvertiblePreferred Stock Amount | Common Stock to Be Issued | Additional Paid In Capital | Accumulated Deficit | Total |
Balance at Dec. 31, 2013 | 33,000,000 | 3,300 | 1,000,000 | 100 | 0 | 11,700 | (109,017) | (93,917) | ||
Forgiveness of debt | $ 96,141 | $ 96,141 | ||||||||
Net Loss | $ (582,947) | $ (582,947) | ||||||||
Balance. at Dec. 31, 2014 | 33,000,000 | 3,300 | 1,000,000 | 100 | 0 | 107,841 | (691,964) | (580,723) | ||
Common stock issued for consulting services | 162,000 | 16 | 122,384 | 122,400 | ||||||
Common stock issued for acquisition of intangible assets and inventory | 5,826,706 | 582 | 982,680 | 983,262 | ||||||
Common stock issued for officer's compensation | 625,000 | 63 | 550,062 | 550,125 | ||||||
Fair value of convertible note for consulting services over the value of note | $ 2,000,000 | $ 2,000,000 | ||||||||
Fair value of series "A" convertible preferred stock issued for consulting services | $ 1,000,000 | $ 100 | $ 5,249,900 | $ 5,250,000 | ||||||
Common stock issued for cash | 20,000 | 2 | 19,998 | 20,000 | ||||||
Common stock to be issued for officer's compensation | $ 52,500 | $ 52,500 | ||||||||
Net Loss | $ (10,092,766) | $ (10,092,766) | ||||||||
Balance at Dec. 31, 2015 | 39,633,706 | 3,963 | 1,000,000 | 100 | 1,000,000 | 100 | 52,500 | 9,032,865 | (10,784,730) | (1,695,202) |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) | 12 Months Ended | |
Dec. 31, 2015 | Dec. 31, 2014 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | ||
Net loss | $ (10,092,766) | $ (582,947) |
Loss from discontinued operations | 0 | 44,696 |
Loss from continuing operations | (10,092,766) | (538,251) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Expenses incurred by related party on behalf of the Company, net | 11,134 | 65,775 |
Impairment loss | 652,265 | 0 |
Inventory written off | 20,845 | 0 |
Depreciation expense | 1,119 | 0 |
Amortization of prepaid services | 1,663,562 | 0 |
Amortization of prepaid insurance | 116,110 | 0 |
Stock based compensation | 5,975,025 | 0 |
Change in operating assets and liabilities: | ||
License fee receivable | 0 | (4,000) |
Accounts payable and accrued expenses | 248,552 | 145,786 |
Inventory | 46,202 | 0 |
Reservation fee deposit | (65,170) | 0 |
Prepaid insurance | (85,000) | (72,329) |
Due to first insurance funding | (31,056) | 54,020 |
NET CASH USED IN OPERATING ACTIVITIES OF CONTINUING OPERATION | (1,539,178) | (348,999) |
NET CASH PROVIDED BY OPERATING ACTIVITIES OF DISCONTINUED OPERATION | 10,000 | |
NET CASH USED IN OPERATING ACTIVITIES | (1,539,178) | (338,999) |
CASH FLOWS FROM INVESTING ACTIVITIES: | ||
Purchase of equipment | (16,780) | 0 |
NET CASH USED IN INVESTING ACTIVITIES OF CONTINUING OPERATION | (16,780) | 0 |
NET CASH USED IN INVESTING ACTIVITIES OF DISCONTINUED OPERATION | 0 | 0 |
NET CASH USED IN INVESTING ACTIVITIES | (16,780) | 0 |
CASH FLOWS FROM FINANCING ACTIVITIES: | ||
Advance - Sanammad Foundation, Inc. | 0 | (5,000) |
Issuance of Common Stock for Cash | 20,000 | |
Loan proceeds from shareholder | 0 | 5,000 |
Proceeds from promissory note - related party | 0 | 1,000,000 |
Proceeds from due to related party | 1,009,000 | |
NET CASH PROVIDED BY FINANCING ACTIVITIES OF CONTINUING OPERATION | 1,029,000 | 1,000,000 |
NET CASH PROVIDED BY FINANCING ACTIVITIES OF DISCONTINUED OPERATION | 0 | 0 |
NET CASH PROVIDED BY FINANCING ACTIVITIES | 1,029,000 | 1,000,000 |
NET CHANGE IN CASH | (526,958) | 661,001 |
CASH BALANCES | ||
Beginning of period | 661,128 | 127 |
End of period | 134,170 | 661,128 |
CASH PAID DURING THE PERIOD FOR: | ||
Interest | 2,217 | 0 |
Income taxes-net of tax refund | 406 | 0 |
SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING AND INVESTING TRANSACTIONS: | ||
Excess fair value of convertible note issued for prepaid services | $ 2,000,000 | $ 0 |
Convertible Series A Preferred stock issued for consulting services | 5,250,000 | 0 |
Convertible Note issued for prepaid services | $ 400,000 | $ 0 |
Acquisition of Intellactual property/inventory through subsidiary acquisition | 983,262 | 0 |
Gain on settlement of debt transferred to additional paid in capital | 0 | 96,141 |
Prepaid insurance paid by related party | $ 0 | $ 65,775 |
ORGANIZATION
ORGANIZATION | 12 Months Ended |
Dec. 31, 2015 | |
ORGANIZATION | |
ORGANIZATION | NOTE 1: ORGANIZATION The Company was originally incorporated in Nevada on November 18, 2010, as Axim International Inc. On July 24, 2014, the Company changed its name to AXIM Biotechnologies, Inc. to better reflect its business operations. The Company's principal executive office is located at 18 East 50th Street, 5th Floor, New York, NY 10022. On August 7, 2014, the Company formed a wholly owned Nevada subsidiary named Axim Holdings, Inc. This subsidiary will be used to help facilitate the anticipated activities planned by the Company. On May 1, 2015 the Company acquired 100% interest in Can Chew License Company a Nevada incorporated licensing Company, through the exchange of its 5,826,706 shares of common stock. In early 2014, the Company discontinued its organic waste marketable by-product business to focus on its anticipated new business to become an innovative biotechnology company working on the treatment of pain, spasticity, anxiety and other medical disorders with the application of cannabinoids based products as well as focusing on research, development and production of pharmaceutical, nutriceutical and cosmetic products as well as procurement of genetically and nano-controlled active ingredients. |
BASIS OF PRESENTATION
BASIS OF PRESENTATION | 12 Months Ended |
Dec. 31, 2015 | |
BASIS OF PRESENTATION: | |
BASIS OF PRESENTATION | NOTE 2: BASIS OF PRESENTATION: The audited consolidated financial statements of AXIM Biotechnologies, Inc. (formerly Axim International, Inc.) On June 9, 2014, the board of directors of the Company adopted a resolution approving a certificate of amendment to the Company's Articles of Incorporation to: (i) change the name of the Company to "AXIM Biotechnologies, Inc.;" and (ii) increase in the number of authorized shares of common stock of the Company from one hundred ninety five million (195,000,000) shares of common stock, par value $0.0001 per share, to three hundred million (300,000,000) shares of common stock, par value $0.0001 per share. |
SIGNIFICANT ACCOUNTING POLICIES
SIGNIFICANT ACCOUNTING POLICIES | 12 Months Ended |
Dec. 31, 2015 | |
SIGNIFICANT ACCOUNTING POLICIES: | |
SIGNIFICANT ACCOUNTING POLICIES | NOTE 3: SIGNIFICANT ACCOUNTING POLICIES Use of estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of revenue and expenses during reporting periods. Actual results could differ from these estimates. Cash equivalents The Company considers all highly liquid investments with original maturities of three months or less at the time of purchase to be cash equivalents. Inventory Inventory consists of finished goods available for sale owned by the Company and is stated at the lower of cost or market. During the year ended December 31, 2015, the Company written off inventory worth $20,845. As of December 31, 2015 the inventory totaled $200,784 and the shelf life of the inventory is set to expire on February 6, 2017. Property and equipment Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using straight-line method over the estimated useful life. New assets and expenditures that extend the useful life of property or equipment are capitalized and depreciated. Expenditures for ordinary repairs and maintenance are charged to operations as incurred. For the year ended December 31, 2015 the Company recorded $1,119 of depreciation expense. Intangible Assets As required by generally accepted accounting principles, trademarks and patents are not amortized since they have an indefinite life. Instead, they are tested annually for impairment. During the year ended December 31, 2015 the Company incurred an impairment loss of $652,265. Intangible assets as of December 31, 2015 amounted to $63,167 net of accumulated impairment losses of $652,265. Revenue Recognition The Company recognizes revenue on four basic criteria that must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management's judgments regarding the fixed nature of the fee charged for services rendered and products delivered and the collectability of those fees. Revenue is generally recognized upon shipment. Revenues from continuing operations recognized for the year December 31, 2015 and 2014 amounted to $49,139 and $0, respectively. Revenues recognized from discontinued operations for the year ended December 31, 2015 and 2014 amounted to $0 and $10,000, respectively. Principles of consolidation The consolidated financial statements include the accounts of Axim Biotechnologies, Inc. and its wholly owned subsidiaries Axim Holdings, Inc. and Can Chew License Company as of December 31, 2015 and 2014. All significant intercompany transactions and balances have been eliminated in consolidation. Fair value of financial instruments The Company follows paragraph 825-10-50-10 Fair Value Measurements and Disclosures of the FASB Accounting Standards Codification for disclosures about fair value of its financial instruments and paragraph 820-10-35-37 of the FASB Accounting Standards Codification ("Paragraph 820-10-35-37") to measure the fair value of its financial instruments. Paragraph 820-10-35-37 establishes a framework for measuring fair value, and expands disclosures about fair value measurements. Income taxes The Company follows Section 740-10, Income tax ("ASC 740-10") Fair Value Measurements and Disclosures of the FASB Accounting Standards Codification, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the Statements of Operations in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including reversals of any existing taxable temporary differences, projected future taxable income, tax planning strategies, and the results of recent operations. If the Company determines that it would be able to realize a deferred tax asset in the future in excess of any recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. The Company adopted section 740-10-25 of the FASB Accounting Standards Codification ("Section 740-10-25"). Section 740-10-25 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under Section 740-10-25, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent (50%) likelihood of being realized upon ultimate settlement. Section 740-10-25 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. The Company had no liabilities for unrecognized income tax benefits according to the provisions of Section 740-10-25. Concentrations of Credit Risk Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such amounts may be in excess of the FDIC insurance limit. The Company does not have accounts receivable and allowance for doubtful accounts at December 31, 2015 and 2014. Net loss per common share Net loss per common share is computed pursuant to section 260-10-45 Earnings Per Share ("ASC 260-10") of the FASB Accounting Standards Codification. Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding and the member potentially outstanding during each period. In periods when a net loss is experienced, only basic net loss per share is calculated because to do otherwise would be anti-dilutive. Stock Based Compensation All stock-based payments to employees and to nonemployee directors for their services as directors, including any grants of restricted stock and stock options, are measured at fair value on the grant date and recognized in the statements of operations as compensation or other expense over the relevant service period. Stock-based payments to nonemployees are recognized as an expense over the period of performance. Such payments are measured at fair value at the earlier of the date a performance commitment is reached or the date performance is completed. In addition, for awards that vest immediately and are non-forfeitable the measurement date is the date the award is issued. Cost of Sales Cost of sales includes the purchase cost of products sold and all costs associated with getting the products to the customers including buying and transportation costs. Research and Development The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development ("ASC 730-10"). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $571,455 and $0 for the years ended December 31, 2015 and 2014. Shipping Costs Shipping and handling costs billed to customers are recorded in sales. Shipping costs incurred by the company are recorded in general and administrative expenses. Recently issued accounting standards In January 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update (ASU) 2016-01, which amends the guidance in U.S. GAAP on the classification and measurement of financial instruments. Changes to the current guidance primarily affect the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The new standard is effective for fiscal years and interim periods beginning after December 15, 2017, and upon adoption, an entity should apply the amendments by means of a cumulative-effect adjustment to the balance sheet at the beginning of the first reporting period in which the guidance is effective. Early adoption is not permitted except for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The Company is currently evaluating the impact of adopting this guidance. In November 2015, the FASB issued (ASU) 2015-17, Balance Sheet Classification of Deferred Taxes. Currently deferred taxes for each tax jurisdiction are presented as a net current asset or liability and net noncurrent asset or liability on the balance sheet. To simplify the presentation, the new guidance requires that deferred tax liabilities and assets for all jurisdictions along with any related valuation allowances be classified as noncurrent in a classified statement of financial position. This guidance is effective for interim and annual reporting periods beginning after December 15, 2016, and early adoption is permitted. The Company has adopted this guidance in the fourth quarter of the year ended December 31, 2015 on a retrospective basis. The adoption of this guidance did not have a material impact on the Company's financial position, results of operations or cash flows, and did not have any effect on prior periods due to the full valuation allowance against the Company's net deferred tax assets. In July 2015, the FASB issued ASU No. 2015-11, "Simplifying the Measurement of Inventory (Topic 330)." ASU 2015-11 simplifies the accounting for the valuation of all inventory not accounted for using the last-in, first-out ("LIFO") method by prescribing that inventory be valued at the lower of cost and net realizable value. ASU 2015-11 is effective for financial statements issued for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016 on a prospective basis. We do not expect the adoption of ASU 2015-11 to have a material effect on our financial position, results of operations or cash flows. In April 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. The amendments in this ASU require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this ASU. The amendments are effective for financial statements issued for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. The amendments are to be applied on a retrospective basis, wherein the balance sheet of each individual period presented is adjusted to reflect the period-specific effects of applying the new guidance. We do not expect the adoption of ASU 2015-03 to have a material effect on our financial position, results of operations or cash flows. In February 2015, the FASB issued ASU No. 2015-02, Consolidation (Topic 810): Amendments to the Consolidation Analysis, which is intended to improve targeted areas of consolidation guidance for legal entities such as limited partnerships, limited liability corporations, and securitization structures (collateralized debt obligations, collateralized loan obligations, and mortgage-backed security transactions). The ASU focuses on the consolidation evaluation for reporting organizations that are required to evaluate whether they should consolidate certain legal entities. In addition to reducing the number of consolidation models from four to two, the new standard simplifies the FASB Accounting Standards Codification and improves current U.S. GAAP by placing more emphasis on risk of loss when determining a controlling financial interest, reducing the frequency of the application of related-party guidance when determining a controlling financial interest in a variable interest entity ("VIE"), and changing consolidation conclusions for companies in several industries that typically make use of limited partnerships or VIEs. The ASU will be effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. We do not expect the adoption of ASU 2015-02 to have a material effect on our financial position, results of operations or cash flows. In November 2014, the FASB issued ASU No. 2014-17, "Business Combinations (Topic 805): Pushdown Accounting." This ASU provides an acquired entity with an option to apply pushdown accounting in its separate financial statements upon occurrence of an event in which an acquirer obtains control of the acquired entity. An acquired entity may elect the option to apply pushdown accounting in the reporting period in which the change-in-control event occurs. If pushdown accounting is applied to an individual change-in-control event, that election is irrevocable. ASU 2014-17 was effective on November 18, 2014. The adoption of ASU 2014-17 did not have any effect on our financial position, results of operations or cash flows. In August 2014, the FASB issued ASU No. 2014-15, "Presentation of Financial Statements - Going Concern (Subtopic 205-40)". ASU 2014-15 provides guidance related to management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern and to provide related footnote disclosure. ASU 2014-15 is effective for annual periods ending after December 15, 2016, and for interim and annual periods thereafter. Early application is permitted. We do not expect the adoption of ASU 2014-15 to have a material effect on our financial position, results of operations or cash flows. Management's evaluations regarding the events and conditions that raise substantial doubt regarding the Company's ability to continue as a going concern have been disclosed in Note 9. In June 2014, the FASB issued ASU No. 2014-12, "Compensation " Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period." This ASU requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. ASU 2014-12 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. We do not expect the adoption of ASU 2014-12 to have a material effect on our financial position, results of operations or cash flows. The amendments also clarify that the guidance in Topic 275, Risks and Uncertainties, is applicable to entities that have not commenced planned principal operations. Other recent accounting pronouncements issued by the FASB and the SEC did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements. |
PREPAID EXPENSES
PREPAID EXPENSES | 12 Months Ended |
Dec. 31, 2015 | |
PREPAID EXPENSES | |
PREPAID EXPENSES | NOTE 4: PREPAID EXPENSES Prepaid expenses consist of the following as of December 31, 2015 and 2014: December 31, 2015 December 31, 2014 Prepaid service contract $ 736,438 $ - Prepaid insurance contract 41,219 72,329 $ 777,657 $ 72,329 |
RESERVATION FEE DEPOSIT
RESERVATION FEE DEPOSIT | 12 Months Ended |
Dec. 31, 2015 | |
RESERVATION FEE DEPOSIT | |
RESERVATION FEE DEPOSIT | NOTE 5: RESERVATION FEE DEPOSIT The Company entered into a reservation agreement with the Municipality of Almere in the Netherlands. In October 2015 the Company paid the reservation fee in the amount of $65,170.The reservation fee deposit gives the company an exclusive right to purchase the building land. Starting in October 2015 the second reservation period was extended for a period of twelve (12) months expiring September 2016. If the company proceeds to purchase the building land the reservation fee will be offset against the purchase price. The Company is not entitled to a refund of the reservation fee if the current agreement in terminated by the Company in the event of insolvency or a moratorium on the transfer or assignment of rights or in the event of a failure to notify or notify on time. The agreement is not transferable. The rights and obligations of this agreement cannot be assigned. The municipality is entitled to terminate the agreement by means of a registered letter if during the reservation period compelling objections exist or arise, or through the insolvency of the Company. |
PROMISSORY NOTE - RELATED PARTY
PROMISSORY NOTE - RELATED PARTY | 12 Months Ended |
Dec. 31, 2015 | |
PROMISSORY NOTE - RELATED PARTY | |
PROMISSORY NOTE - RELATED PARTY | NOTE 6: PROMISSORY NOTE - RELATED PARTY On August 8, 2014 the Company entered into a Promissory Note Agreement with CanChew Biotechnologies, LLC (CCB), a related party (the owners of CCB also own 90% of the outstanding shares of the Company), under which it borrowed $1,000,000 to fund working capital. The loan is a demand note which bears interest at a rate of 7% annually. The Promissory Note Agreement was amended effective January 1, 2015. The amended Promissory Note bears an annual interest rate of 3%. All other terms and conditions shall remain in full force and effect. The following table summarizes promissory note payable as of December 31, 2015 and 2014: December 31, 2015 December 31, 2014 Promissory note payable, due on demand, interest at 3% and 7%, respectively. $ 1,000,000 $ 1,000,000 Accrued interest $ 57,726 28,053 $ $1,057,726 $ 1,028,053 For the years ended December 31, 2015 and 2014 the Company recognized interest expense of $29,673 and $28,053, respectively, included in Accounts payable and accrued liabilities. |
STOCKHOLDERS' DEFICIT
STOCKHOLDERS' DEFICIT | 12 Months Ended |
Dec. 31, 2015 | |
STOCKHOLDERS' DEFICIT {1} | |
STOCKHOLDERS' DEFICIT | NOTE 7: STOCKHOLDERS' DEFICIT Preferred stock The Company has authorized 5,000,000 shares of preferred stock, with a par value of $0.0001 per share, of which 1,000,000 shares were designated as Series A Convertible Preferred Stock. Undesignated Preferred stock As of December 31, 2015 and 2014, the Company had 1,000,000 shares of undesignated preferred stock issued and outstanding. Series A Convertible Preferred stock Each share of Series A Convertible Preferred Stock is convertible into 5 shares of Company's common stock. As of December 31, 2015 and 2014, the Company had 1,000,000 and 0; respectively, shares of Series A convertible preferred stock issued and outstanding. Liquidation Preference: In the event of any liquidation, dissolution or winding up of the company, whether voluntary or involuntary (a "Liquidation"), the assets of the company available for distribution to its stockholders shall be distributed as follows. The holders of the Series A Convertible Preferred stock shall be entitled to receive , prior to the holders of the other series preferred stock and prior and in preference to any distribution of the assets or surplus funds of the company to the holders of any other shares of stock of the company by reason of their ownership of such stock: (i) all shares of common stock an any subsidiary of the company which are held by the company: and (ii) an amount equal to $1.00 per share with respect to each share of Series A Convertible Preferred stock, plus all declared but unpaid dividends with respect to such share. Voting Rights: Those holders of the company's preferred shares shall have one hundred (100) votes per share of preferred stock held. On March 26, 2015 the Board of Directors approved the issuance of 1,000,000 shares of series A convertible preferred stock. to Sanammad Foundation USA a related party of the company. On May 15, 2015 Sanammad Foundation USA transferred the 1,000,000 shares of series A convertible preferred stock to Treo Holdings, LLC a related party of the company. Treo Holdings, LLC provided the company with consultancy services including corporate planning and restructuring of the organization. Each share of series A convertible preferred stock can be converted at the option of the holder and subject to notice requirements at any time, into five shares of the company's common stock. The Company calculated fair value of the convertible series A convertible preferred stock at $5,250,000 and recorded as compensation expense. Common stock The Company has authorized 300,000,000 shares of common stock, with a par value of $0.0001 per share. As of December 31, 2015 and 2014, the Company had 39,633,706 and 33,000,000 shares of common stock issued and outstanding, respectively. On January 15, 2015, the Company issued 18,000 shares of common stock as compensation for services performed for the Company by certain directors of the Company. The fair value of the underlying stock on the date of issuance was at $2.00 per share. The Company determined the fair value of the common stock was more readily determinable than the fair value of the services rendered. For the year ended December 31, 2015, the Company recorded $36,000 of compensation expense in the accompanying consolidated financial statements. On June 13, 2014, the Company entered into an employment agreement with Dr. George Anastassov, its Chief Executive Officer, Chief Financial Officer and Secretary. On June 13, 2015, following twelve (12) months of continuous employment the Company issued 500,000 restricted shares of the Company's common stock based upon the average ten (10) day closing price immediately preceding the grant date, as quoted on Yahoo.com. For the year ended December 31, 2015, the Company recorded $473,000 of compensation expense in the accompanying consolidated financial statements. On September 13, 2015 following fifteen (15) months of continuous employment, and every three months thereafter, the Company was obligated to issue 125,000 restricted shares of the Company's common stock based upon the average ten (10) day closing price immediately preceding the grant date, as quoted on Yahoo.com. On October 28, 2015 the board of directors approved the issuance of the stock grant. As of December 31, 2015 the company recorded $77,125 of compensation expense in the accompanying consolidated statement of operations. On December 13, 2015 the Company was obligated to issue 125,000 restricted shares of the Company's common stock based upon the average ten (10) day closing price immediately preceding the grant date, as quoted on Yahoo.com. As of December 31, 2015 the Company accrued $52,500 of compensation expense in the accompanying consolidated financial statements, the shares were issued subsequently. On May 1, 2015 the Canchew License Company entered into a licensing agreement with CanChew Biotechnologies, LLC ("Canchew"). The agreement provides that in exchange for its' intellectual property and inventory, Canchew will receive 5,826,706 restricted shares of the Company common stock and sliding scale royalties based on gross receipts. Management has determined the cost of the licensing agreement of $715,432 and inventory of $267,830 on the basis of lower of cost incurred or market value. For the year ended December 31, 2015 the Company recorded an impairment loss of $652,265. On July 14, 2015 the Board of Directors of the Company approved the issuance of 20,000 restricted common stock pursuant to the Common Stock Purchase Agreement "Agreement" which is selling, on a best efforts basis, up to $3,000,000 worth of the Company common stock, $0.0001 par value at a purchase price of $1.00 per share. The purchase price of the underlying stock on the date of issuance was $1.00 per share. During the year ended December 31, 2015 the Company received $20,000 from the investor in exchange for 20,000 restricted common shares of the Company. On December 29, 2015 the Board of Directors of the Company approved the issuance of 144,000 unrestricted shares of common stock as compensation for services performed for the Company by certain consultants of the Company. The fair value of the underlying stock on the date of issuance was at $0.60 per share. The Company determined the fair value of the common stock was more readily determinable than the fair value of the services rendered. For the year ended December 31, 2015, the Company recorded $86,400 of compensation expense in the accompanying consolidated financial statements. |
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS | 12 Months Ended |
Dec. 31, 2015 | |
RELATED PARTY TRANSACTIONS: | |
RELATED PARTY TRANSACTIONS | NOTE 8: RELATED PARTY TRANSACTIONS Effective November 26, 2012, the Company entered into a separate Convertible Loan Agreement with its ex-President, under which it borrowed $50,000, in the form of a non-interest bearing note. The Company used the proceeds of this loan to fund the purchase of license rights under the November 26, 2012, agreement with Omega Research Corporation. The note was transferred to an outside party Cross & Company, Inc. in 2015. The loan is convertible into common stock at $0.10 per share at the option of the lender any time after February 28, 2013. As of December 31, 2015 the loan has not been converted. On May 21, 2014, the Company President advanced an additional $5,000 to the Company to fund working capital needs. This brings the total amount due to shareholder to $55,000 as of December 31, 2015, including convertible loan. On August 8, 2014, the Company entered into a Promissory Note Agreement with CanChew Biotechnologies, LLC (CCB), a related party (The owners of CCB also own 90% of the outstanding shares of the Company), under which it borrowed $1,000,000 to fund working capital. The loan is a demand note which bears interest at a rate of 7% annually. The Promissory Note Agreement was amended effective January 1, 2015. The amended Promissory Note bears an annual interest rate of 3%. All other terms and conditions shall remain in full force and effect. For the year ended December 31, 2015 and 2014 the Company charged $29,673 and $28,053, respectively as interest expenses to operation (refer note 6). On June 25, 2014, the Company received a non interest bearing advance from CanChew Biotechnologies, LLC (CCB) of $30,000 to pay the down payment on its D & O liability insurance. In addition the Company during 2014 was advanced an additional $35,775 for operating expenses principally for the owner's salary. For the year ended December 31, 2015 the Company received additional advance of $1,020,135 for operation expenses. The advance is non-interest bearing and is due on demand. The total outstanding due to related party as of December 31, 2015 and 2014 is $1,085,910 and $65,775, respectively. |
GOING CONCERN
GOING CONCERN | 12 Months Ended |
Dec. 31, 2015 | |
GOING CONCERN: | |
GOING CONCERN | NOTE 9: GOING CONCERN The Company's consolidated financial statements have been presented assuming that the Company will continue as a going concern. As shown in the consolidated financial statements, the Company has negative working capital of $ 1,374,030, has an accumulated deficit of $10,784,730, has cash used in operating activities of continuing operations $1,539,178 and presently does not have the resources to accomplish its objectives during the next twelve months. These conditions raise substantial doubt about the ability of the Company to continue as a going concern. The consolidated The Company intends to raise additional capital through private placements of debt and equity securities, but there can be no assurance that these funds will be available on terms acceptable to the Company, or will be sufficient to enable the Company to fully complete its development activities or sustain operations. If the Company is unable to raise sufficient additional funds, it will have to develop and implement a plan to further extend payables, reduce overhead, or scale back its current business plan until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful. |
DUE TO FIRST INSURANCE FUNDING
DUE TO FIRST INSURANCE FUNDING | 12 Months Ended |
Dec. 31, 2015 | |
DUE TO FIRST INSURANCE FUNDING | |
DUE TO FIRST INSURANCE FUNDING | NOTE 10: DUE TO FIRST INSURANCE FUNDING The Company financed the purchase of its D & O insurance with a note due to First Insurance Funding. The principal amount financed was $120,000. Interest is due on the unpaid balance at a rate of 6.189% per annum. The total amount of interest due under the terms of the note is $3,116. The term of the note is for nine months commencing August 25, 2014. Payments are due for nine installments in the amount of $13,680 each, which includes principal and interest, commencing August 25, 2014. The total outstanding due to First Insurance Funding as of December 31, 2015 and 2014 is $0 and $54,020, respectively. The Company financed the purchase of its D & O insurance renewal with a note due to First Insurance Funding. The principal amount financed was $85,000 during the year ended December 31, 2015. Interest is due on the unpaid balance at a rate of 5.25% per annum. The total amount of interest due under the terms of the note is $1,496. The term of the note is for nine months commencing July 25, 2015. Payments are due for nine installments in the amount of $7,722 each, which includes principal and interest, commencing July 25, 2015. The total outstanding due to First Insurance Funding as of December 31, 2015 and 2014 is $22,964 and $0, respectively, is included under prepaid expenses. |
CONVERTIBLE NOTE PAYABLE
CONVERTIBLE NOTE PAYABLE | 12 Months Ended |
Dec. 31, 2015 | |
CONVERTIBLE NOTE PAYABLE | |
CONVERTIBLE NOTE PAYABLE | NOTE 11: CONVERTIBLE NOTE PAYABLE On April 21, 2015 the Company entered into a one year consultancy agreement with Cross & Company an independent contractor terminating on April 21, 2016. In exchange for these consultancy services the Company agreed to pay Cross & Company $400,000 payable by the issuance of a convertible note at a rate of 4% per annum at the conversion price of $0.10 per share. Interest shall accrue until the maturity date, April 21, 2025 at which time all principal and interest accrued shall be due and payable. The holder of the note has the right, at the holder's option, at any time prior to payment in full of the principal balance in whole or in part, into fully paid and nonassessable "S-8 shares" of the company's common stock pursuant to a Stock Incentive Plan (see note 12). As of December 31, 2015 the loan has not been converted. For the year ended December 31, 2015 the Company accrued interest in the amount of $11,197. The Company calculated fair value of the convertible note at $2,400,000 as prepaid expenses and the excess value of $2,000,000 over the value of note was credited to additional paid in capital. The prepaid expense was amortized over the period of twelve month of service. During the year ended December 31, 2015, the Company amortized $1,663,562. As of December 31, 2015, the total unamortized prepaid expense of $736,438 is included in prepaid expenses (note 4). |
STOCK INCENTIVE PLAN
STOCK INCENTIVE PLAN | 12 Months Ended |
Dec. 31, 2015 | |
STOCK INCENTIVE PLAN: | |
STOCK INCENTIVE PLAN | NOTE 12: STOCK INCENTIVE PLAN Effective May 29, 2015 the company adopted a stock incentive plan under which eligible persons or vendors whom provide the company services may be afforded an opportunity to acquire an equity interest in the company in exchange for those services provided. The Company has reserved 10,000,000 shares of its common stock for issuance under this plan. |
COMMITMENT AND CONTINGENCIES
COMMITMENT AND CONTINGENCIES | 12 Months Ended |
Dec. 31, 2015 | |
COMMITMENT AND CONTINGENCIES | |
COMMITMENT AND CONTINGENCIES | NOTE 13: COMMITMENT AND CONTINGENCIES On June 13, 2014, the Company entered into an employment agreement with Dr. George Anastassov, its Chief Executive Officer, Chief Financial Officer and Secretary. The agreement's effective date is June 1, 2014. The initial term of the agreement is one year. The agreement renews each year until terminated by the Company or Dr. Anastassov. Cash remuneration is $20,000 per month payable bi-monthly. On November 15, 2014 the Company and Municipality of Almere, the province of Flevoland, The Netherlands entered into a "reservation agreement" whereas the Company is interested in the construction of a manufacturing facility for the production of a new pharmaceutical, nutraceutical and consumer products as well as a center for R&D, on the plots of building and land located at Lagekant, the Netherlands. The reservation agreement is for a term of one year and expires on November 15, 2015. The Company must notify the Municipality of Almere whether or not it wishes to be considered for the purchase of the building and land on or before the end of the reservation agreement. If the municipality has not received notification on time before the end of the reservation period whether it wishes to purchase the building and land and also does not receive notification during the three (3) working days following said date, the right to reservation of the Company lapses. The municipality is then fully at liberty to offer the building land to any other prospective purchasers. The Company is entitled to terminate this agreement in writing without this giving rise to any payment obligation. The Company incurred a reservation fee after February 15, 2015 in the amount of $65,170. The purchase price has been determined to be $985,680 Euros exclusive of VAT and transfer taxes. The land parcel is 6000 square meters. The Company made the reservation payment on October 14, 2015 in the amount of $32,480 and the remaining balance of $32,690 was paid on October 15, 2015 (Note 5). |
INCOME TAXES
INCOME TAXES | 12 Months Ended |
Dec. 31, 2015 | |
INCOME TAXES: | |
INCOME TAXES | NOTE 14: INCOME TAXES The Company utilizes ASC 740 "Income Taxes", which requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statement or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. For the year ended December 31, 2015, the Company had available for U.S federal income tax purposes net operating loss carryovers of approximately $3,600,000, which will expire on various dates in the next twenty (20) years. The net operating loss carryovers may be subject to limitations under Internal Revenue Code due to significant changes in the Company's ownership. The Company has provided a full valuation allowance against the full amount of the net operating loss benefit, since, in the opinion of management, based upon the earnings history of the Company it is more likely than not that the benefits will not be realized. The provision for income taxes differ from the amount of income tax determined by applying the applicable U.S statutory rate to losses before income tax expense for the period ended December 31, 2015 and 2014 as follows: 2015 2014 Statutory federal income tax rate (35.0%) (35.0%) Statutory state and local income tax rate (8.25%), net of federal benefit (5.4%) (5.4%) Change in valuation allowance (40.4%) (40.4%) Effective tax rate 0.00% (0.00%) Deferred income taxes result from temporary differences in the recognition of income and expenses for financial reporting purposes and for tax purposes. The tax effect of these temporary differences representing deferred tax asset result principally from the following: 2015 2014 Deferred tax assets : - Net operating loss carry forward $ 1,443,800 $ 278,100 Less: valuation allowance (1,443,800) (278,100) Net deferred tax asset $ - $ - |
SUBSEQUENT EVENT
SUBSEQUENT EVENT | 12 Months Ended |
Dec. 31, 2015 | |
SUBSEQUENT EVENT | |
SUBSEQUENT EVENT | NOTE 15: SUBSEQUENT EVENT Effective January 1, 2016, the Company entered into a 12 month employment agreement, at a compensation rate of $126,000 annually, with Lekhram Changoer to serve as our Chief Technology Officer. Following 3 months of continuous employment, and every three months thereafter, Mr. Changoer will receive either; at the sole option of the Company, 120,000 restricted shares of Company common stock; or the financial equivalent in cash, based upon the average 10 day closing price as of the Company's common stock immediately preceding the grant date, as quoted on Yahoo Finance.com. |
Accounting Policies (Policies)
Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2015 | |
Accounting Policies: | |
Use of Estimates, Policy | Use of estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported amounts of revenue and expenses during reporting periods. Actual results could differ from these estimates. |
Cash Equivalents, Policy | Cash equivalents |
Inventory, Policy | Inventory Inventory consists of finished goods available for sale owned by the Company and is stated at the lower of cost or market. During the year ended December 31, 2015, the Company written off inventory worth $20,845. As of December 31, 2015 the inventory totaled $200,784 and the shelf life of the inventory is set to expire on February 6, 2017. |
Property and equipment | Property and equipment Property and equipment are carried at cost less accumulated depreciation. Depreciation is computed using straight-line method over the estimated useful life. New assets and expenditures that extend the useful life of property or equipment are capitalized and depreciated. Expenditures for ordinary repairs and maintenance are charged to operations as incurred. For the year ended December 31, 2015 the Company recorded $1,119 of depreciation expense. |
Intangible Assets, Policy | Intangible Assets As required by generally accepted accounting principles, trademarks and patents are not amortized since they have an indefinite life. Instead, they are tested annually for impairment. During the year ended December 31, 2015 the Company incurred an impairment loss of $652,265. Intangible assets as of December 31, 2015 amounted to $63,167 net of accumulated impairment losses of $652,265. |
Revenue Recognition, Policy | Revenue Recognition The Company recognizes revenue on four basic criteria that must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the fee is fixed or determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management's judgments regarding the fixed nature of the fee charged for services rendered and products delivered and the collectability of those fees. Revenue is generally recognized upon shipment. Revenues from continuing operations recognized for the year December 31, 2015 and 2014 amounted to $49,139 and $0, respectively. Revenues recognized from discontinued operations for the year ended December 31, 2015 and 2014 amounted to $0 and $10,000, respectively. |
Principles of consolidation | Principles of consolidation The consolidated financial statements include the accounts of Axim Biotechnologies, Inc. and its wholly owned subsidiaries Axim Holdings, Inc. and Can Chew License Company as of December 31, 2015 and 2014. All significant intercompany transactions and balances have been eliminated in consolidation. |
Fair Value of Financial Instruments, Policy | Fair value of financial instruments The Company follows paragraph 825-10-50-10 Fair Value Measurements and Disclosures of the FASB Accounting Standards Codification for disclosures about fair value of its financial instruments and paragraph 820-10-35-37 of the FASB Accounting Standards Codification ("Paragraph 820-10-35-37") to measure the fair value of its financial instruments. Paragraph 820-10-35-37 establishes a framework for measuring fair value, and expands disclosures about fair value measurements. |
Income Taxes, Policy | Income taxes The Company follows Section 740-10, Income tax ("ASC 740-10") Fair Value Measurements and Disclosures of the FASB Accounting Standards Codification, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the Statements of Operations in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including reversals of any existing taxable temporary differences, projected future taxable income, tax planning strategies, and the results of recent operations. If the Company determines that it would be able to realize a deferred tax asset in the future in excess of any recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. The Company adopted section 740-10-25 of the FASB Accounting Standards Codification ("Section 740-10-25"). Section 740-10-25 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under Section 740-10-25, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent (50%) likelihood of being realized upon ultimate settlement. Section 740-10-25 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. The Company had no liabilities for unrecognized income tax benefits according to the provisions of Section 740-10-25. |
Concentrations of Credit Risk | Concentrations of Credit Risk Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such amounts may be in excess of the FDIC insurance limit. The Company does not have accounts receivable and allowance for doubtful accounts at December 31, 2015 and 2014. |
Net loss per common share | Net loss per common share Net loss per common share is computed pursuant to section 260-10-45 Earnings Per Share ("ASC 260-10") of the FASB Accounting Standards Codification. Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding and the member potentially outstanding during each period. In periods when a net loss is experienced, only basic net loss per share is calculated because to do otherwise would be anti-dilutive. |
Stock Based Compensation | Stock Based Compensation All stock-based payments to employees and to nonemployee directors for their services as directors, including any grants of restricted stock and stock options, are measured at fair value on the grant date and recognized in the statements of operations as compensation or other expense over the relevant service period. Stock-based payments to nonemployees are recognized as an expense over the period of performance. Such payments are measured at fair value at the earlier of the date a performance commitment is reached or the date performance is completed. In addition, for awards that vest immediately and are non-forfeitable the measurement date is the date the award is issued. |
Cost of Sales, Policy | Cost of Sales Cost of sales includes the purchase cost of products sold and all costs associated with getting the products to the customers including buying and transportation costs. |
Research and Development | Research and Development The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development ("ASC 730-10"). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $571,455 and $0 for the years ended December 31, 2015 and 2014. |
Shipping Costs | Shipping Costs Shipping and handling costs billed to customers are recorded in sales. Shipping costs incurred by the company are recorded in general and administrative expenses. |
Recently issued accounting standards | Recently issued accounting standards In January 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update (ASU) 2016-01, which amends the guidance in U.S. GAAP on the classification and measurement of financial instruments. Changes to the current guidance primarily affect the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, the ASU clarifies guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The new standard is effective for fiscal years and interim periods beginning after December 15, 2017, and upon adoption, an entity should apply the amendments by means of a cumulative-effect adjustment to the balance sheet at the beginning of the first reporting period in which the guidance is effective. Early adoption is not permitted except for the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income. The Company is currently evaluating the impact of adopting this guidance. In November 2015, the FASB issued (ASU) 2015-17, Balance Sheet Classification of Deferred Taxes. Currently deferred taxes for each tax jurisdiction are presented as a net current asset or liability and net noncurrent asset or liability on the balance sheet. To simplify the presentation, the new guidance requires that deferred tax liabilities and assets for all jurisdictions along with any related valuation allowances be classified as noncurrent in a classified statement of financial position. This guidance is effective for interim and annual reporting periods beginning after December 15, 2016, and early adoption is permitted. The Company has adopted this guidance in the fourth quarter of the year ended December 31, 2015 on a retrospective basis. The adoption of this guidance did not have a material impact on the Company's financial position, results of operations or cash flows, and did not have any effect on prior periods due to the full valuation allowance against the Company's net deferred tax assets. In July 2015, the FASB issued ASU No. 2015-11, "Simplifying the Measurement of Inventory (Topic 330)." ASU 2015-11 simplifies the accounting for the valuation of all inventory not accounted for using the last-in, first-out ("LIFO") method by prescribing that inventory be valued at the lower of cost and net realizable value. ASU 2015-11 is effective for financial statements issued for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016 on a prospective basis. We do not expect the adoption of ASU 2015-11 to have a material effect on our financial position, results of operations or cash flows. In April 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2015-03, Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs. The amendments in this ASU require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this ASU. The amendments are effective for financial statements issued for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. The amendments are to be applied on a retrospective basis, wherein the balance sheet of each individual period presented is adjusted to reflect the period-specific effects of applying the new guidance. We do not expect the adoption of ASU 2015-03 to have a material effect on our financial position, results of operations or cash flows. In February 2015, the FASB issued ASU No. 2015-02, Consolidation (Topic 810): Amendments to the Consolidation Analysis, which is intended to improve targeted areas of consolidation guidance for legal entities such as limited partnerships, limited liability corporations, and securitization structures (collateralized debt obligations, collateralized loan obligations, and mortgage-backed security transactions). The ASU focuses on the consolidation evaluation for reporting organizations that are required to evaluate whether they should consolidate certain legal entities. In addition to reducing the number of consolidation models from four to two, the new standard simplifies the FASB Accounting Standards Codification and improves current U.S. GAAP by placing more emphasis on risk of loss when determining a controlling financial interest, reducing the frequency of the application of related-party guidance when determining a controlling financial interest in a variable interest entity ("VIE"), and changing consolidation conclusions for companies in several industries that typically make use of limited partnerships or VIEs. The ASU will be effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. We do not expect the adoption of ASU 2015-02 to have a material effect on our financial position, results of operations or cash flows. In November 2014, the FASB issued ASU No. 2014-17, "Business Combinations (Topic 805): Pushdown Accounting." This ASU provides an acquired entity with an option to apply pushdown accounting in its separate financial statements upon occurrence of an event in which an acquirer obtains control of the acquired entity. An acquired entity may elect the option to apply pushdown accounting in the reporting period in which the change-in-control event occurs. If pushdown accounting is applied to an individual change-in-control event, that election is irrevocable. ASU 2014-17 was effective on November 18, 2014. The adoption of ASU 2014-17 did not have any effect on our financial position, results of operations or cash flows. In August 2014, the FASB issued ASU No. 2014-15, "Presentation of Financial Statements - Going Concern (Subtopic 205-40)". ASU 2014-15 provides guidance related to management's responsibility to evaluate whether there is substantial doubt about an entity's ability to continue as a going concern and to provide related footnote disclosure. ASU 2014-15 is effective for annual periods ending after December 15, 2016, and for interim and annual periods thereafter. Early application is permitted. We do not expect the adoption of ASU 2014-15 to have a material effect on our financial position, results of operations or cash flows. Management's evaluations regarding the events and conditions that raise substantial doubt regarding the Company's ability to continue as a going concern have been disclosed in Note 9. In June 2014, the FASB issued ASU No. 2014-12, "Compensation " Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period." This ASU requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. ASU 2014-12 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. We do not expect the adoption of ASU 2014-12 to have a material effect on our financial position, results of operations or cash flows. The amendments also clarify that the guidance in Topic 275, Risks and Uncertainties, is applicable to entities that have not commenced planned principal operations. Other recent accounting pronouncements issued by the FASB and the SEC did not or are not believed by management to have a material impact on the Company's present or future consolidated financial statements. |
PREPAID EXPENSES (TABLES)
PREPAID EXPENSES (TABLES) | 12 Months Ended |
Dec. 31, 2015 | |
PREPAID EXPENSES (TABLES): | |
PREPAID EXPENSES (TABLES) | Prepaid expenses consist of the following as of December 31, 2015 and 2014: December 31, 2015 December 31, 2014 Prepaid service contract $ 736,438 $ - Prepaid insurance contract 41,219 72,329 $ 777,657 $ 72,329 |
Schedule of Summary of Promisso
Schedule of Summary of Promissory Notes Payable (Tables) | 12 Months Ended |
Dec. 31, 2015 | |
Schedule of Summary of Promissory Notes Payable: | |
Schedule of Summary of Promissory Notes Payable | The following table summarizes promissory note payable as of December 31, 2015 and 2014: December 31, 2015 December 31, 2014 Promissory note payable, due on demand, interest at 3% and 7%, respectively. $ 1,000,000 $ 1,000,000 Accrued interest $ 57,726 28,053 $ $1,057,726 $ 1,028,053 |
INCOME TAXES (TABLES)
INCOME TAXES (TABLES) | 12 Months Ended |
Dec. 31, 2015 | |
INCOME TAXES (TABLES): | |
Schedule of Components of Income Tax Expense (Benefit) | The provision for income taxes differ from the amount of income tax determined by applying the applicable U.S statutory rate to losses before income tax expense for the period ended December 31, 2015 and 2014 as follows: 2015 2014 Statutory federal income tax rate (35.0%) (35.0%) Statutory state and local income tax rate (8.25%), net of federal benefit (5.4%) (5.4%) Change in valuation allowance (40.4%) (40.4%) Effective tax rate 0.00% (0.00%) |
Schedule of Deferred Tax Assets and Liabilities | Deferred income taxes result from temporary differences in the recognition of income and expenses for financial reporting purposes and for tax purposes. The tax effect of these temporary differences representing deferred tax asset result principally from the following: 2015 2014 Deferred tax assets : - Net operating loss carry forward $ 1,443,800 $ 278,100 Less: valuation allowance (1,443,800) (278,100) Net deferred tax asset $ - $ - |
ORGANIZATION (Details)
ORGANIZATION (Details) | May. 01, 2015shares |
ORGANIZATION Details | |
Acquired interest in Can Chew License Company | 100.00% |
Acquired interest in Can Chew License Company through the exchange of shares of common stock | 5,826,706 |
BASIS OF PRESENTATION (Details)
BASIS OF PRESENTATION (Details) | Jun. 09, 2014$ / sharesshares |
BASIS OF PRESENTATION Details | |
Number of authorized shares of common stock of the Company before the amendment | 195,000,000 |
Number of authorized shares of common stock of the Company after the amendment | 300,000,000 |
Par value of common stock per share | $ / shares | $ 0.0001 |
SIGNIFICANT ACCOUNTING POLICI28
SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2015 | Dec. 31, 2014 | |
Depreciation Details | ||
Depreciation expense | $ 1,119 | |
Intangible Assets Details | ||
Impairment loss | 652,265 | |
Intangible assets | 63,167 | |
Net of accumulated impairment losses | 652,265 | |
Revenue Recognition | ||
Revenues from continuing operations recognized | 49,139 | $ 0 |
Revenues recognized from discontinued operations | 0 | 10,000 |
Research and Development | ||
The Company incurred research and development expenses | $ 571,455 | $ 0 |
Prepaid expenses consist of the
Prepaid expenses consist of the following (Details) - USD ($) | Dec. 31, 2015 | Dec. 31, 2014 |
Prepaid expenses consist of the following | ||
Prepaid service contract | $ 736,438 | |
Prepaid insurance contract | 41,219 | $ 72,329 |
Total prepaid expense | 777,657 | 72,329 |
Company recognized amortization expense | $ 1,779,672 | $ 77,671 |
RELATED PARTY PROMISSORY NOTE (
RELATED PARTY PROMISSORY NOTE (Details) - USD ($) | Dec. 31, 2015 | Dec. 31, 2014 | Aug. 08, 2014 |
Related party Promissory note | |||
Promissory note payable, due on demand, interest at 3% and 7%, respectively | $ 1,000,000 | $ 1,000,000 | |
Accrued interest on note | 57,726 | 28,053 | |
Total amount of note payable | 1,057,726 | 1,028,053 | |
CCB own outstanding shares of the Company | 90.00% | ||
Working capital fund | $ 1,000,000 | ||
Interest rate annually | 7.00% | ||
Company recognized interest expense | $ 29,673 | $ 28,053 |
PREFERRED STOCk (Details)
PREFERRED STOCk (Details) | Dec. 31, 2015$ / sharesshares | May. 15, 2015USD ($)shares | Mar. 26, 2015shares | Dec. 31, 2014$ / sharesshares |
Preferred stock | ||||
Total authorized shares of preferred stock | 5,000,000 | 5,000,000 | ||
Per share value of Preferred stock | $ / shares | $ 0.0001 | $ 0.0001 | ||
Shares designated as Series A Convertible Preferred Stock. | 1,000,000 | 1,000,000 | ||
Undesignated shares of Preferred Stock. | 1,000,000 | 1,000,000 | ||
Shares of Series A convertible preferred stock issued and outstanding | 1,000,000 | 0 | ||
Conversion rights of every share of Series A Convertible preferred stock in to common shares | 5 | |||
Liquidation Preference of every share of Series A Convertible preferred stock | $ / shares | $ 1 | |||
Votes per share of preferred stock held. | 100 | |||
Board of Directors approved the issuance of shares of series A convertible preferred stock. to Sanammad Foundation USA | 1,000,000 | |||
Sanammad Foundation USA transferred the shares of series A convertible preferred stock to Treo Holdings, LLC | 1,000,000 | |||
Fair value of the convertible series A convertible preferred stock | $ | $ 5,250,000 |
COMMON STOCK (Details)
COMMON STOCK (Details) - $ / shares | Dec. 31, 2015 | Dec. 31, 2014 |
Common stock | ||
Company has authorized shares of common stock | 300,000,000 | 300,000,000 |
Company had shares of common stock issued and outstanding | 39,633,706 | 33,000,000 |
Per share value of common stock | $ 0.0001 | $ 0.0001 |
Common stock - Services (Detail
Common stock - Services (Details) - USD ($) | Dec. 31, 2015 | Jan. 15, 2015 |
Common stock - Services | ||
Company issued shares of common stock as compensation for services performed | 18,000 | |
The fair value of the underlying stock on the date of issuance per share | $ 2 | |
Company recorded compensation expense for services | $ 36,000 |
Common stock - Employment agree
Common stock - Employment agreement (Details) - USD ($) | Dec. 31, 2015 | Sep. 13, 2015 | Jun. 13, 2015 |
Common stock - Employment agreement | |||
Company issued restricted shares of the Company's common stock based upon the average ten (10) day closing price immediately preceding the grant date | 125,000 | 125,000 | 500,000 |
Company recorded compensation expense for employment services | $ 473,000 | ||
Company recorded compensation expense in the accompanying consolidated statement of operations | 77,125 | ||
Company accrued compensation expense in the accompanying consolidated financial statements | $ 52,500 |
Common stock - Licensing agreem
Common stock - Licensing agreement (Details) - USD ($) | Dec. 31, 2015 | May. 01, 2015 |
Common stock - Licensing agreement | ||
Company entered into a licensing agreement and issued restricted shares of the Company common stock | 5,826,706 | |
Management has determined the cost of the licensing agreement | $ 715,432 | |
Management has determined the cost of inventory | $ 267,830 | |
Company recorded an impairment loss as per agreement | $ 652,265 |
Issue of restricted common stoc
Issue of restricted common stock (Details) - USD ($) | Dec. 31, 2015 | Jul. 14, 2015 |
Issue of restricted common stock | ||
Issue of restricted common stock pursuant to the Common Stock Purchase Agreement | 20,000 | 20,000 |
Worth of the Company common stock sold as per agreement | $ 3,000,000 | |
The purchase price of the underlying stock on the date of issuance | $ 1 | |
Company received from the investor in exchange for restricted common shares of the Company | $ 20,000 |
Issue of unrestricted shares of
Issue of unrestricted shares of common stock (Details) - USD ($) | Dec. 31, 2015 | Dec. 29, 2015 |
Issue of unrestricted shares of common stock | ||
issue of unrestricted shares of common stock to certain consultants of the Company | 144,000 | |
The fair value of the underlying stock on the date of issuance | $ 0.60 | |
Company recorded compensation expense | $ 86,400 |
RELATED PARTY AGREEMENTS (Detai
RELATED PARTY AGREEMENTS (Details) - USD ($) | Dec. 31, 2015 | Dec. 31, 2014 | Aug. 08, 2014 | Jun. 25, 2014 | May. 21, 2014 |
Related party agreements | |||||
Company president advanced to fund working capital needs | $ 45,002 | $ 5,000 | |||
Company entered into a separate Convertible Loan Agreement with its President and borrowed | $ 50,000 | ||||
The loan is convertible into common stock at a price per share | $ 0.10 | ||||
Total amount due to shareholder including convertible loan | $ 55,000 | ||||
Company entered into a Promissory Note Agreement with CanChew Biotechnologies, LLC and borrowed to fund working capital | $ 1,000,000 | ||||
Interest rate on note | 7.00% | ||||
Interest expense charged by the company in the period | 28,053 | ||||
Company received a non interest bearing advance from CCB | $ 30,000 | ||||
Advanced an additional operating expenses | $ 35,775 | ||||
Total outstanding due to related party | $ 1,085,910 | $ 65,775 |
Interest expenses (Details)
Interest expenses (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2015 | Dec. 31, 2014 | |
Interest expenses Details | ||
Company charged interest expenses to operation | $ 29,673 | $ 28,053 |
Company received additional advance for operation expenses | $ 1,020,135 | $ 35,775 |
GOING CONCERN (Details)
GOING CONCERN (Details) | Dec. 31, 2015USD ($) |
GOING CONCERN DETAILS | |
Company has negative working capital | $ 1,374,030 |
Incurred accumulated deficit in the period | 10,784,730 |
Cash used in operating activities of continuing operations | $ 1,539,178 |
FIRST INSURANCE FUNDING (Detail
FIRST INSURANCE FUNDING (Details) - USD ($) | Dec. 31, 2015 | Dec. 31, 2014 | Aug. 25, 2014 |
First Insurance Funding | |||
The principle amount financed | $ 120,000 | ||
Interest due on the unpaid balance at a rate per annum | 6.19% | ||
The total amount of interest due under the terms of the note | $ 3,116 | ||
Payments are due for nine installments in the amount and includes principle and interest | $ 13,680 | ||
The total outstanding due to First Insurance Funding | $ 0 | $ 54,020 |
DUE TO FIRST INSURANCE FUNDING
DUE TO FIRST INSURANCE FUNDING (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2015 | Dec. 31, 2014 | |
DUE TO FIRST INSURANCE FUNDING Details | ||
The principle amount financed | $ 85,000 | |
Interest due on the unpaid balance at a rate per annum | 5.25% | |
The total amount of interest due under the terms of the note | $ 1,496 | |
Payments are due for nine installments in the amount and includes principle and interest | 7,722 | |
The total outstanding due to First Insurance Funding | $ 22,964 | $ 0 |
CONVERTIBLE NOTE PAYABLE (Detai
CONVERTIBLE NOTE PAYABLE (Details) - USD ($) | 12 Months Ended | |
Dec. 31, 2015 | Dec. 31, 2014 | |
CONVERTIBLE NOTE PAYABLE DETAILS | ||
Calculated fair value of the convertible note as prepaid expenses | $ 2,400,000 | $ 2,400,000 |
Excess value over the value of note credited to additional paid in capital | 2,000,000 | 2,000,000 |
Accrued interest | 11,197 | |
Amortization of prepaid expense | 1,663,562 | $ 1,065,205 |
Unamortization of prepaid expense | $ 736,438 |
NOTE PAYABLE (Details)
NOTE PAYABLE (Details) | Apr. 21, 2015USD ($)$ / shares |
NOTE PAYABLE Details | |
Amount to be paid to Cross & Company for consultancy services | $ | $ 400,000 |
Convertible note at a rate per annum | 4.00% |
Conversion price per share | $ / shares | $ 0.10 |
STOCK INCENTIVE PLAN (Details)
STOCK INCENTIVE PLAN (Details) | May. 29, 2015shares |
STOCK INCENTIVE PLAN DETAILS | |
Reserved shares of common stock for issuance under plan | 10,000,000 |
EMPLOYMENT AGREEMENT AND COMMIT
EMPLOYMENT AGREEMENT AND COMMITMENTS (Details) - USD ($) | Oct. 15, 2015 | Oct. 14, 2015 | Feb. 15, 2015 | Jan. 15, 2015 | Jun. 13, 2014 |
Employment agreement and commitments | |||||
Cash remuneration in the amount per month payable bi-monthly | $ 18,000 | $ 20,000 | |||
Reservation fee in euros | $ 32,480 | $ 65,170 | |||
Purchase price exclusive of VAT and transfer taxes in euros | $ 985,680 | ||||
Reservation payment remaining balance was paid on | $ 32,690 |
Income tax expense (Details)
Income tax expense (Details) | Dec. 31, 2015 | Dec. 31, 2014 |
income tax expense Details | ||
Statutory federal income tax rate | (35.00%) | (35.00%) |
Statutory state and local income tax rate (8.25%), net of federal benefit | (5.40%) | (5.40%) |
Change in valuation allowance | (40.40%) | (40.40%) |
Effective tax rate | 0.00% | 0.00% |
Deferred income taxes (Details)
Deferred income taxes (Details) - USD ($) | Dec. 31, 2015 | Dec. 31, 2014 |
Deferred tax assets : | ||
Net operating loss carry forward | $ 1,443,800 | $ 278,100 |
Less: valuation allowance | (1,443,800) | $ (278,100) |
Net deferred tax asset | $ 0 |
Net Operating loss carryovers (
Net Operating loss carryovers (Details) | 12 Months Ended |
Dec. 31, 2015USD ($) | |
Net Operating loss carryovers Details | |
Federal income tax net operating loss carryovers | $ 3,600,000 |
SUBSEQUENT EVENT (Details)
SUBSEQUENT EVENT (Details) | Jan. 01, 2016USD ($)shares |
SUBSEQUENT EVENT Details | |
Company entered into employment agreement at a compensation rate | $ | $ 126,000 |
Restricted shares of Company common stock | shares | 120,000 |